Regional Economics: Theory and Practice
 

Comparing the drug provision systems in Europe and the USA. Valuable lessons for Russia

Vol. 16, Iss. 4, APRIL 2018

Received: 14 February 2018

Received in revised form: 26 February 2018

Accepted: 5 March 2018

Available online: 14 April 2018

Subject Heading: SOCIO-ECONOMIC POLICY

JEL Classification: E62, E64, F20

Pages: 624–639

https://doi.org/10.24891/re.16.4.624

Aityan T.V. Lomonosov Moscow State University, Moscow, Russian Federation
aytyant@gmail.com

https://orcid.org/0000-0002-1410-9360

Importance This article explores the public drug supply systems in the USA and European countries.
Objectives The article aims to confirm the hypothesis that the countries of Europe provide a higher level of availability of medicines and quality of life for the population at relatively lower expenditures on pharmaceuticals compared to the United States.
Methods For the research, I used the methods of systems, structural, and comparative analyses. The works of leading experts in the fields of public administration and health, legislative and regulatory documents, statistical data from international databases on the industry for the last five years are the information and theoretical basis of the research.
Results Despite the current lag behind the U.S. in the field of innovation and R&D expenditures, European countries manage to effectively perform the task of controlling the quantity and quality of public spending on medicines. The key advantages of the system are the availability of institutions evaluating the drug cost effectiveness, the availability of national formularies, control of pricing at the stage of post-marketing registration, support of the market of authorized generic drugs stimulating drastic and significant innovations in the market.
Conclusions The European system of State regulation of pharmaceutical industry provides a high quality of medicines and optimum level of public expenditures. The basic principles of the system can be successfully implemented within the Russian insurance system.

Keywords: pharmaceutical industry, pricing, public health costs, USA, Europe

References:

  1. Bellanger M.-M., Mossé P. Santé, Grandes tendances. L'état de la France, La Découverte, 2011, pp. 69–75. URL: https://halshs.archives-ouvertes.fr/halshs-00778561
  2. DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics, 2016, vol. 47, pp. 20–33. URL: https://doi.org/10.1016/j.jhealeco.2016.01.012
  3. Duguet E. The Effect of the Incremental R&D Tax Credit on the Private Funding of R&D: An Econometric Evaluation of French Firm Level Data. Revue d'economie politique, 2012, vol. 122, iss. 3, pp. 405–435. URL: https://www.cairn.info/revue-d-economie-politique-2012-3-page-405.htm
  4. Ferrario A., Kanavos P. Dealing with Uncertainty and High Prices of New Medicines: A Comparative Analysis of the Use of Managed Entry Agreements in Belgium, England, the Netherlands and Sweden. Social Science & Medicine, 2015, vol. 124, pp. 39–47. URL: https://doi.org/10.1016/j.socscimed.2014.11.003
  5. Godman B., Shrank W., Andersen M. et al. Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. Frontiers in Pharmacology, 2011, 7 January. URL: https://doi.org/10.3389/fphar.2010.00141
  6. Eichler H.-G., Baird L.G., Barker R. et al. From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients. Clinical Pharmacology & Therapeutics, 2015, vol. 97, no. 3, pp. 234–246. URL: http://onlinelibrary.wiley.com/doi/10.1002/cpt.59/full
  7. Kroneman M., de Jong Ju.D. The Basic Benefit Package: Composition and Exceptions to the Rules. A Case Study. Health Policy, 2015, vol. 119, iss. 3, pp. 245–251. URL: https://doi.org/10.1016/j.healthpol.2015.01.013
  8. Mackenbach J.P., Kulhánová I., Bopp M. et al. Variations in the Relation between Education and Cause-Specific Mortality in 19 European Populations: A Test of the “Fundamental Causes” Theory of Social Inequalities in Health. Social Science & Medicine, 2015, vol. 127, pp. 51–62. URL: https://doi.org/10.1016/j.socscimed.2014.05.021
  9. Martins S.F., Foppe van Mil J.W., da Costa F.A. The Organizational Framework of Community Pharmacies in Europe. International Journal of Clinical Pharmacy, 2015, vol. 37, iss. 5, pp. 896–905. URL: https://doi.org/10.1007/s11096-015-0140-1
  10. Nicod E., Kanavos P. Commonalities and Differences in HTA Outcomes: A Comparative Analysis of Five Countries and Implications for Coverage Decisions. Health Policy, 2012, vol. 108, iss. 2-3, pp. 167–177. URL: https://doi.org/10.1016/j.healthpol.2012.09.012
  11. Ognyanova D., Zentner A., Busse R. Pharmaceutical Reform 2010 in Germany: Striking a Balance between Innovation and Affordability. Eurohealth, 2011, vol. 17, no. 1, pp. 11–13. URL: http://www.euro.who.int/__data/assets/pdf_file/0017/147104/Eurohealth_Vol-17_No-1_web.pdf

View all articles of issue

 

ISSN 2311-8733 (Online)
ISSN 2073-1477 (Print)

Journal current issue

Vol. 16, Iss. 6
June 2018

Archive